Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial 17beta-estradiol dose for treating vasomotor symptoms.

M Notelovitz1, J P Lenihan, M McDermott

  • 1Women's Medical and Diagnostic Center, The Climacteric Clinic, Gainesville, Florida, USA.

Obstetrics and Gynecology
|April 25, 2000
PubMed
Summary

Different doses of 17beta-estradiol (E2) effectively reduce hot flushes in menopausal women. The 1 mg dose of oral micronized E2 demonstrated the most beneficial initial treatment for vasomotor symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adrenal crisis following COVID-19 vaccination in steroid dependant patients assessed in the Emergency Department.

Irish medical journal·2025
Same author

Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis.

Archives of osteoporosis·2023
Same author

Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer.

Breast cancer research and treatment·2022
Same author

Leptomeningeal Relapse of Embryonal Rhabdomyosarcoma after 15 years.

Irish medical journal·2020
Same author

Burkitt Lymphoma/Leukaemia in Children & Young Adolescents.

Irish medical journal·2020
Same author

Acoustic Supercoupling in a Zero-Compressibility Waveguide.

Research (Washington, D.C.)·2019

Area of Science:

  • Reproductive Endocrinology
  • Pharmacology
  • Women's Health

Background:

  • Vasomotor symptoms, such as hot flushes, are common during menopause.
  • Hormone therapy, including 17beta-estradiol (E2), is a primary treatment for these symptoms.
  • Optimal dosing for E2 in managing menopausal vasomotor symptoms requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of various doses of oral micronized 17beta-estradiol (E2) in alleviating moderate to severe hot flushes.
  • To establish a dose-response relationship for E2 in treating menopausal vasomotor symptoms.

Main Methods:

  • A randomized, double-masked, placebo-controlled trial was conducted over 12 weeks.
  • 333 menopausal women with moderate to severe hot flushes were assigned to receive placebo or 0.25 mg, 0.5 mg, 1 mg, or 2 mg of oral micronized 17beta-E2.

Related Experiment Videos

  • Daily hot flush frequency and severity were recorded.

    • Main Results:

    • A significant linear dose-response relationship was observed between increased 17beta-E2 dosage and reduced hot flush frequency (P <.001).
    • Significant reduction in hot flushes compared to placebo was noted at week 4 for 1 mg and 2 mg doses.
    • By week 12, all E2 doses except 0.25 mg showed significant efficacy in reducing hot flushes compared to placebo (P <.001).

    Conclusions:

    • Oral micronized 17beta-estradiol exhibits a clear dose-response effect for reducing moderate to severe hot flushes in menopausal women.
    • The 1 mg dose of 17beta-estradiol is suggested as an effective and useful initial dose for managing these symptoms.
    • Higher doses, particularly 2 mg, may lead to increased adverse event-related discontinuations, warranting careful consideration.